a nonsignificant trendp = 0.192
Among patients with greater comorbidities (ACCI ≥6), hypofractionation was associated with a nonsignificant trend toward improved PFS (HR: 0.68, 95% CI: 0.38-1.21, p = 0.192).
Among patients with greater comorbidities (ACCI ≥6), hypofractionation was associated with a nonsignificant trend toward improved PFS (HR: 0.68, 95% CI: 0.38-1.21, p = 0.192).
In the ACCI ≥ 6 group, although not statistically significant, patients receiving concurrent hRT with TMZ showed a trend toward a better OS than did those receiving Stupp (HR = 0.51, 95% CI: 0.17–1.53, p = 0.23).
In these models, the ACCI approached borderline significance but remained nonsignificant overall.